BCAL Diagnostics Issues Shares, Complies with Regulations

BCAL Diagnostics Limited (AU:BDX) has released an update.

BCAL Diagnostics Limited has announced the issuance of 869,565 shares at $0.115 each to advisers without public disclosure, in compliance with the Corporations Act. The company affirms adherence to all necessary regulations as of the announcement date and reports no undisclosed ‘excluded information’. BCAL continues to focus on its mission to advance breast cancer diagnosis through its innovative non-invasive blood test.

For further insights into AU:BDX stock, check out TipRanks’ Stock Analysis page.